Pharmexa receives US patent on the GV1001 vaccine for chemotherapy
26-Apr-2006
Pharmexa's issued patent claims cover specific peptides, including the GV1001 vaccine, and their use in cancer immunotherapy. In addition, divisional patent applications have been filed in both Europe and the USA.
Most read news
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.